Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet (Q28576328)

2

1 reference

31 January 2017

Céline Wetterwald

3

1 reference

31 January 2017

Gilles Simard

4

1 reference

31 January 2017

Yves Malthièry

5

1 reference

31 January 2017

Pierre-Henri Ducluzeau

American Journal of Physiology - Endocrinology and Metabolism

6

1 reference

31 January 2017

1 November 2009

1 reference

31 January 2017

1 reference

31 January 2017

297

1 reference

31 January 2017

5

1 reference

31 January 2017

E1162–1170

1 reference

31 January 2017

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Regulation of oxidative phosphorylation in the mammalian cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The expression of receptors for endocannabinoids in human and rodent skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Role of adiponectin in human skeletal muscle bioenergetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The endocannabinoid system: a general view and latest additions

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Endocannabinoids and the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The molecular logic of endocannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Cellular energy utilization and molecular origin of standard metabolic rate in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009

Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00169.2009